Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases  

作　　者：Tielong Chen Yilan Hu Quanquan Ding Jing Yu Fubing Wang Fengling Luo Xiao-Lian Zhang 

机构地区：[1]State Key Laboratory of Virology and Department of Immunology and Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University School of Medicine [2]Zhongnan Hospital of Wuhan University [3]Department of Immunology, Wuhan University of Science and Technology School of Medicine [4]Hubei Cancer Hospital

出　　处：《Virologica Sinica》2015年第4期249-260,共12页中国病毒学（英文版）

基　　金：supported by grants from the Natio nal Natural Science Foundation of China (31221061, 31270176 and 31370197);National Outstanding You th Foundation of China (81025008);the 973 Program of China (2012CB720604);the Program for Changjia ng Scholars and Innovative Research Team in Universi ty (IRT1030);the Hubei Province’s Outstanding Medical Academic Leader Program (523-276003);the Developm ent Fund for Collaborative Innovation Center of Glycosc ience of Shandong University;the Science and Tech nology Program of Wuhan (201150530141)

摘　　要：Human ficolin-2 is an important lectin complement pathway activator that is secreted from liver cells and has been implicated as an anti-infection innate immune molecule. However, the role of ficolin-2 protein and its dynamic changes over the course of and in the prognosis of chronic hepatitis B(CHB) and hepatocellular carcinoma(HCC) remain unclear. In this study, we analyzed ficolin-2 protein expression in a cohort of individuals with CHB infection, HCC and cirrhosis. A sandwich enzyme-linked immunosorbent assay(ELISA) method was used to measure serum ficolin-2 concentrations. Ficolin-2 expression in liver tissues was detected by immunohistochemical staining. Serum ficolin-2 concentrations in CHB patients were significantly higher than in healthy controls and HBV carriers. After 48 weeks of routine amelioration liver function treatment, serum ficolin-2 concentrations decreased and were positively correlated with favorable alanine aminotransferase(ALT), HBV DNA and HBe Ag-seroconversion outcomes. Interestingly, we observed much lower expression of serum and intrahepatic ficolin-2 in HCC and cirrhosis compared with healthy controls. Our findings suggest that serum and intrahepatic ficolin-2 levels may be considered one of the indicators for the response of chronic HBV infection, HCC and cirrhosis.Human ficolin-2 is an important lectin complement pathway activator that is secreted from liver cells and has been implicated as an anti-infection innate immune molecule. However, the role of ficolin-2 protein and its dynamic changes over the course of and in the prognosis of chronic hepatitis B(CHB) and hepatocellular carcinoma(HCC) remain unclear. In this study, we analyzed ficolin-2 protein expression in a cohort of individuals with CHB infection, HCC and cirrhosis. A sandwich enzyme-linked immunosorbent assay(ELISA) method was used to measure serum ficolin-2 concentrations. Ficolin-2 expression in liver tissues was detected by immunohistochemical staining. Serum ficolin-2 concentrations in CHB patients were significantly higher than in healthy controls and HBV carriers. After 48 weeks of routine amelioration liver function treatment, serum ficolin-2 concentrations decreased and were positively correlated with favorable alanine aminotransferase(ALT), HBV DNA and HBe Ag-seroconversion outcomes. Interestingly, we observed much lower expression of serum and intrahepatic ficolin-2 in HCC and cirrhosis compared with healthy controls. Our findings suggest that serum and intrahepatic ficolin-2 levels may be considered one of the indicators for the response of chronic HBV infection, HCC and cirrhosis.

关 键 词：ficolin-2 CHRONIC HEPATITIS B(CHB) HEPATOCELLULAR 

分 类 号：R512.62[医药卫生—内科学]